Alexis Peyroles Departs OSE Immunotherapeutics as CEO

OSE Immunotherapeutics SA has announced the departure of Alexis Peyroles as chief executive officer. Dominique Costantini, current chairwoman of OSE Immunotherapeutics’ Board of Directors, and previously CEO from 2012 to 2018, has been appointed interim chief executive officer, effective immediately. A search for a new CEO has been launched with the assistance of a leading executive search firm.

Peyroles is stepping down for health reasons and he remains committed to OSE’s success. He will continue to support the company in a consulting capacity for the upcoming months to ensure a smooth transition.

During this transition period, Costantini will rely on OSE’s reinforced leadership team, including notably Laurence de Schoulepnikoff, today chief business officer, appointed as chief operating officer of the company, functions which she previously held at AMAL Therapeutics.

Costantini, commented, “We thank Alexis for his strong involvement and wish him the very best. Thanks to Alexis’s leadership, as company COO since OSE’s early days and then as CEO since 2018, OSE became a significant player in immunology & inflammation and immuno-oncology. Three major pharma partnering agreements were signed, a diversified pipeline of best and first-in-class products was built, and a very strong team has been set up. Alexis will continue to support the company as an advisor to ensure the best transition possible.” 

 Costantini continued, “I warmly thank the Board of Directors for their trust as we are entering a new phase of growth, a transformative time focused on advancing our innovative clinical and preclinical assets in immunology & inflammation and immuno-oncology. We are committed to ensuring a successful evolution in recruiting the best candidate to lead this next step for OSE.”